Evidence map›Paper›PMID 40184625›Full record

ArticleAdvanced science (Weinheim, Baden-Wurttemberg, Germany)2025

Icaritin Represses Autophagy to Promote Colorectal Cancer Cell Apoptosis and Sensitized Low-Temperature Photothermal Therapy via Targeting HSP90-TXNDC9 Interactions.

Dan He, Siliang Chen, Xiaoyun Wang, Xiang Wen, Changyang Gong, Lei Liu, Gu He

Abstract read
In one paragraph

Article in Advanced science (Weinheim, Baden-Wurttemberg, Germany), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed.

  1. Review
  2. Review
  3. Article
  4. Article
  5. Article
  6. Review
  7. Review
  8. A Novel Autophagy InhibitorResearch (Washington, D.C.) · 2026
    Article
  9. Article
  10. Article
  11. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Dan HeDivision of Head & Neck Tumor Multimodality Treatment, Cancer Center and Department of Dermatology & Venerology, West China Hospital, Sichuan University, Chengdu, 610041, China.
Siliang ChenDivision of Head & Neck Tumor Multimodality Treatment, Cancer Center and Department of Dermatology & Venerology, West China Hospital, Sichuan University, Chengdu, 610041, China.
Xiaoyun WangDivision of Head & Neck Tumor Multimodality Treatment, Cancer Center and Department of Dermatology & Venerology, West China Hospital, Sichuan University, Chengdu, 610041, China.
Xiang WenDivision of Head & Neck Tumor Multimodality Treatment, Cancer Center and Department of Dermatology & Venerology, West China Hospital, Sichuan University, Chengdu, 610041, China.
Changyang GongDivision of Head & Neck Tumor Multimodality Treatment, Cancer Center and Department of Dermatology & Venerology, West China Hospital, Sichuan University, Chengdu, 610041, China.
Lei LiuDivision of Head & Neck Tumor Multimodality Treatment, Cancer Center and Department of Dermatology & Venerology, West China Hospital, Sichuan University, Chengdu, 610041, China.
Gu HeDivision of Head & Neck Tumor Multimodality Treatment, Cancer Center and Department of Dermatology & Venerology, West China Hospital, Sichuan University, Chengdu, 610041, China.ORCID https://orcid.org/0000-0002-1536-8882

Funding

1.3.5 project for disciplines of excellence, West China Hospital, Sichuan University 2023HXBH032China Postdoctoral Science Foundation 2023T160446China Postdoctoral Science Foundation 2024M752232China Postdoctoral Science Foundation and Xinglin Scholar Research Promotion Project of CDUTCMNational Natural Science Foundation of China 22177084National Natural Science Foundation of China 82304063National Natural Science Foundation of China 82404175Scientific Research Project of China Baoyuan CBYI202103Sichuan Science and Technology Program 2025NSFTD0031Sichuan Science and Technology Program 2025ZNSFC1625
6 · The paper itself

Abstract

Colorectal cancer (CRC) ranks among the leading causes of cancer-related dea ths worldwide, and the rising incidence and mortality of CRC underscores the urgent need for better understanding and management strategies. Icaritin (ICA) is the metabolites of icariin, a natural flavonoid glycoside compound derived from the stems and leaves of Epimedium. It has broad spectrum antitumor activity and inhibits the proliferation, migration, and invasion of CRC cells, and causes S phase cell cycle arrest. It exerts its antitumor effects against CRC through repressing autophagy to promote CRC cell apoptosis via interfering the HSP90-TXNDC9 interactions. The safety and efficacy of ICA are also affirmed in a mouse xenograft model. Additionally, to test whether ICA exerts synergistic effects with low-temperature photothermal therapy (LTPTT), a novel nanodrug delivery system, employing SiO

Indexed as

ApoptosisAutophagyColorectal NeoplasmsFlavonoidsHSP90 Heat-Shock ProteinsPhotothermal TherapyAnimalsCell Line, TumorHumansMiceMice, Inbred BALB CMice, NudeXenograft Model Antitumor AssaysFlavonoidsHSP90 Heat-Shock Proteinsicaritinautophagycolorectal cancerHSP90icaritinphotothermal therapy

Identifiers

PMID40184625
PMCPMC12120733

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.